



help joe get better sooner*

The only antiviral medication for adults and children aged ≥1 year effective against influenza types A and B

TREAT AND PREVENT WITH TAMIFLU

- Significantly reduces duration of flu illness —1.3 days faster
• Postexposure prophylaxis helps prevent flu transmission in children and adults
• Generally well tolerated in children since 2000


*1.3 days faster



treat. prevent. protect. Tamiflu oseltamivir phosphate

help joe get better sooner – treat early*

TAMIFLU SIGNIFICANTLY REDUCES DURATION OF ILLNESS



A randomized, placebo-controlled, double-blind study conducted January through March 1998 that included 629 healthy, nonimmunized adults aged 18 to 65 years.

The primary efficacy endpoint was time to resolution of illness, defined as time from study drug initiation to time of alleviation of symptoms, among individuals with influenza infection.

- When initiated within 2 days of symptom onset, TAMIFLU significantly reduced flu duration by 1.3 days compared with placebo
• Symptom relief was defined as the first 24-hour period in which all influenza symptoms were scored as mild or none
• Serious bacterial infections may begin with influenza-like symptoms or may coexist with or occur as complications during the course of influenza.

*Within 2 days of symptom onset.

SAFETY INFORMATION

There is no evidence for efficacy against any illness caused by agents other than influenza types A and B.

Treatment efficacy in subjects with chronic cardiac and/or respiratory disease has not been established. No difference in the incidence of complications was observed between the treatment and placebo groups in this population.

Safety and efficacy of repeated treatment or prophylaxis courses have not been studied.

Influenza can be associated with a variety of neurologic and behavioral symptoms, which can include events such as hallucinations, delirium and abnormal behavior, in some cases resulting in fatal outcomes. These events may occur in the setting of encephalitis or encephalopathy but can occur without obvious severe disease.

In postmarketing experience, rare cases of anaphylaxis and serious skin reactions, including toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme, have been reported with TAMIFLU.

The most common adverse events reported >1% of patients treated with TAMIFLU and more commonly than in patients treated with placebo are:

- Treatment of adult and pediatric patients – nausea, vomiting.
• Prophylaxis of adult and pediatric patients – nausea, vomiting, abdominal pain.


Vaccination is considered the first line of defense against influenza.

Please see accompanying complete Prescribing Information.



act sooner¹ to help protect mom from the flu

TAMIFLU HELPS PREVENT FLU TRANSMISSION IN ADULTS⁴



Number of household contacts aged ≥12 years=405

A cluster-randomized, double-blind, placebo-controlled study conducted at 76 centers in North America and Europe during the winter of 1998-1999 that involved 377 index cases: 43% with laboratory-confirmed influenza infection.²

The primary efficacy endpoint was the proportion of contacts of an influenza-positive index case with laboratory-confirmed clinical influenza²

TREATMENT

Easy to take, easy to prescribe

- One 75 mg capsule twice daily for 5 days
 - In patients with creatinine clearance between 10 mL/min and 30 mL/min, one 75 mg capsule once daily for 5 days*
- Treatment should begin within 2 days of symptom onset
- May be taken with or without food
- When taken with food, tolerability may be enhanced in some patients

PROPHYLAXIS

For postexposure prophylaxis

- One 75 mg capsule once daily for at least 10 days
 - In patients with creatinine clearance between 10 mL/min and 30 mL/min, one 75 mg capsule every other day or 30 mg oral suspension once daily*
- Administration should begin within 2 days of exposure to an infected close contact

For seasonal prophylaxis

- One 75 mg capsule once daily during a community outbreak
 - In patients with creatinine clearance between 10 mL/min and 30 mL/min, one 75 mg capsule every other day or 30 mg oral suspension once daily*
- Safety and efficacy have been demonstrated for up to 6 weeks
- Duration of protection lasts for as long as dosing is continued

*No recommended dosing regimens are available for patients undergoing routine hemodialysis and continuous peritoneal dialysis treatment with end-stage renal disease.

INDICATIONS

TAMIFLU is indicated for the treatment of uncomplicated influenza caused by viruses types A and B in patients 1 year and older who have been symptomatic for no more than 2 days.

TAMIFLU is also indicated for the prophylaxis of influenza in patients ≥1 year. TAMIFLU is not a substitute for early and annual vaccination.

Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use TAMIFLU.

References

1. Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. *J Infect Dis.* 2004;189(3):440-449.
2. Welliver R, Monto AS, Carewicz O, et al, for the Oseltamivir Post Exposure Prophylaxis Investigator Group. Effectiveness of oseltamivir in preventing influenza in household contacts. A randomized clinical trial. *JAMA.* 2001;285(6):748-754.
3. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. A randomized controlled trial. *JAMA.* 2000;283:1016-1024.

Please see accompanying complete Prescribing Information.
Please see Important Safety Information on reverse.

act sooner to help protect mom

The only antiviral medication for adults and children aged ≥1 year effective against influenza types A and B

TREAT AND PREVENT WITH TAMIFLU

- Significantly reduces duration of flu illness—1.3 days faster
- Postexposure prophylaxis helps prevent flu transmission in children and adults^{1,2}
- Generally well tolerated in children since 2000

Roche

Roche Laboratories Inc.
340 Kingsland Street
Nutley, New Jersey 07110-1199
www.rocheusa.com

Tamiflu[®]
oseltamivir phosphate
treat. prevent. protect.